MX2016017381A - Nucleosidos sustituidos, nucleotidos y analogos de los mismos. - Google Patents
Nucleosidos sustituidos, nucleotidos y analogos de los mismos.Info
- Publication number
- MX2016017381A MX2016017381A MX2016017381A MX2016017381A MX2016017381A MX 2016017381 A MX2016017381 A MX 2016017381A MX 2016017381 A MX2016017381 A MX 2016017381A MX 2016017381 A MX2016017381 A MX 2016017381A MX 2016017381 A MX2016017381 A MX 2016017381A
- Authority
- MX
- Mexico
- Prior art keywords
- analogs
- nucleotides
- substituted nucleosides
- nucleosides
- nucleotide analogs
- Prior art date
Links
- 125000003729 nucleotide group Chemical group 0.000 title abstract 4
- 239000002777 nucleoside Substances 0.000 title abstract 3
- 125000003835 nucleoside group Chemical group 0.000 title abstract 3
- 239000002773 nucleotide Substances 0.000 title 1
- 241000711950 Filoviridae Species 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462016219P | 2014-06-24 | 2014-06-24 | |
| US201462034629P | 2014-08-07 | 2014-08-07 | |
| US201462061819P | 2014-10-09 | 2014-10-09 | |
| PCT/US2015/036958 WO2015200205A1 (en) | 2014-06-24 | 2015-06-22 | Substituted nucleosides, nucleotides and analogs thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016017381A true MX2016017381A (es) | 2017-08-14 |
Family
ID=54868667
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016017381A MX2016017381A (es) | 2014-06-24 | 2015-06-22 | Nucleosidos sustituidos, nucleotidos y analogos de los mismos. |
Country Status (17)
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2794627T3 (pl) | 2011-12-22 | 2019-04-30 | Alios Biopharma Inc | Podstawione nukleozydy, nukleotydy i ich analogi |
| US8980865B2 (en) | 2011-12-22 | 2015-03-17 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
| NZ631601A (en) | 2012-03-21 | 2016-06-24 | Alios Biopharma Inc | Solid forms of a thiophosphoramidate nucleotide prodrug |
| USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| EA201590943A1 (ru) | 2012-12-21 | 2016-01-29 | Алиос Биофарма, Инк. | Замещенные нуклеозиды, нуклеотиды и их аналоги |
| HK1216535A1 (zh) | 2012-12-21 | 2016-11-18 | Alios Biopharma, Inc. | 取代的核苷、核苷酸及其類似物 |
| US9504705B2 (en) | 2013-04-05 | 2016-11-29 | Alios Biopharma, Inc. | Hepatitis C viral infection treatment using a combination of compounds |
| ES2952714T3 (es) | 2013-06-26 | 2023-11-03 | Janssen Pharmaceuticals Inc | Nucleósidos sustituidos, nucleótidos y análogos de los mismos |
| AU2014302715B2 (en) | 2013-06-26 | 2018-12-06 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| SG10201804835VA (en) | 2013-10-11 | 2018-07-30 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
| SG11201610599TA (en) | 2014-06-24 | 2017-01-27 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
| WO2015200205A1 (en) | 2014-06-24 | 2015-12-30 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| EA031726B1 (ru) | 2014-09-26 | 2019-02-28 | Рибосайенс Ллк | 4'-винилзамещенные производные нуклеозидов в качестве ингибиторов репликации рнк респираторно-синцитиального вируса |
| US20170246209A1 (en) * | 2014-10-06 | 2017-08-31 | Nantkwest, Inc. | Treating viral hemorrhagic fever with nk-92 cells |
| CN107108681B (zh) | 2014-10-28 | 2021-04-06 | 詹森生物制药有限公司 | 制备取代的核苷类似物的方法 |
| MA41213A (fr) | 2014-12-19 | 2017-10-24 | Alios Biopharma Inc | Nucléosides substitués, nucléotides et analogues de ceux-ci |
| MA41441A (fr) | 2014-12-19 | 2017-12-12 | Alios Biopharma Inc | Nucléosides substitués, nucléotides et analogues de ceux-ci |
| CN107427529A (zh) | 2014-12-26 | 2017-12-01 | 埃莫里大学 | N4‑羟基胞苷和衍生物及与其相关的抗病毒用途 |
| KR102363946B1 (ko) | 2015-03-06 | 2022-02-17 | 아테아 파마슈티컬즈, 인크. | HCV 치료를 위한 β-D-2'-데옥시-2'-α-플루오로-2'-β-C-치환된-2-변형된-N6-치환된 퓨린 뉴클레오티드 |
| CA2979216A1 (en) | 2015-03-11 | 2016-09-15 | Alios Biopharma, Inc. | Aza-pyridone compounds and uses thereof |
| EA201892448A1 (ru) * | 2016-04-28 | 2019-06-28 | Эмори Юниверсити | Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения |
| US10202412B2 (en) | 2016-07-08 | 2019-02-12 | Atea Pharmaceuticals, Inc. | β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections |
| HRP20220278T1 (hr) | 2016-09-07 | 2022-05-13 | Atea Pharmaceuticals, Inc. | 2'-supstituirani-n6-supstituirani purinski nukleotidi za liječenje bolesti izazvanih rnk virusima |
| IL295609B2 (en) | 2017-02-01 | 2023-11-01 | Atea Pharmaceuticals Inc | Nucleotide hemisulfate salt for the treatment of hepatitis C virus |
| JP2020518578A (ja) | 2017-05-01 | 2020-06-25 | ギリアード サイエンシーズ， インコーポレイテッド | （Ｓ）−２−エチルブチル２−（（（Ｓ）−（（（２Ｒ，３Ｓ，４Ｒ，５Ｒ）−５−（４−アミノピロロ［２，１−ｆ］［１，２，４］トリアジン−７−イル）−５−シアノ−３，４−ジヒドロキシテトラヒドロフラン−２−イル）メトキシ）（フェノキシ）ホスホリル）アミノ）プロパノエートの結晶形態 |
| CA3077489A1 (en) | 2017-07-11 | 2019-01-17 | Gilead Sciences, Inc. | Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections |
| CR20200126A (es) | 2017-09-18 | 2020-07-11 | Janssen Biopharma Inc | Nucleósidos sustituidos, nucleótidos y análogos de estos |
| ES2995458T3 (en) | 2017-12-07 | 2025-02-10 | Univ Emory | N4-hydroxycytidine derivative and anti-viral uses related thereto |
| CN119633010A (zh) * | 2018-03-07 | 2025-03-18 | 埃默里大学 | 含4′-卤素的核苷酸和核苷治疗组合物以及其相关用途 |
| WO2019200005A1 (en) | 2018-04-10 | 2019-10-17 | Atea Pharmaceuticals, Inc. | Treatment of hcv infected patients with cirrhosis |
| MA55200A (fr) | 2019-03-06 | 2022-01-12 | Glaxosmithkline Ip No 2 Ltd | Composés utiles dans la thérapie du vih |
| CA3134613A1 (en) * | 2019-04-02 | 2020-10-08 | Aligos Therapeutics, Inc. | Compounds targeting prmt5 |
| CN118766947A (zh) | 2020-01-27 | 2024-10-15 | 吉利德科学公司 | 用于治疗SARS CoV-2感染的方法 |
| TWI874791B (zh) | 2020-02-18 | 2025-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| EP4644394A2 (en) | 2020-02-18 | 2025-11-05 | Gilead Sciences, Inc. | Antiviral compounds |
| TWI794742B (zh) | 2020-02-18 | 2023-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| TWI890963B (zh) | 2020-03-12 | 2025-07-21 | 美商基利科學股份有限公司 | 1'-氰基核苷之製備方法 |
| AU2021237718B2 (en) | 2020-03-20 | 2023-09-21 | Gilead Sciences, Inc. | Prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| CN115362004A (zh) | 2020-04-06 | 2022-11-18 | 吉利德科学公司 | 1’-氰基取代的碳核苷类似物的吸入制剂 |
| UY39172A (es) * | 2020-04-14 | 2021-10-29 | Janssen Sciences Ireland Unlimited Co | Análogos de nucleósido bi- y monocíclicos para el tratamiento de la hepatitis e |
| ES3041698T3 (en) | 2020-05-29 | 2025-11-13 | Gilead Sciences Inc | Remdesivir for the treatment of viral infections |
| JP2023531524A (ja) | 2020-06-24 | 2023-07-24 | ギリアード サイエンシーズ， インコーポレイテッド | １’－シアノヌクレオシド類似体及びその使用 |
| JP7559223B2 (ja) | 2020-08-24 | 2024-10-01 | ギリアード サイエンシーズ， インコーポレイテッド | リン脂質化合物及びその使用 |
| IL300453A (en) | 2020-08-27 | 2023-04-01 | Gilead Sciences Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS |
| TW202344257A (zh) | 2020-10-16 | 2023-11-16 | 美商基利科學股份有限公司 | 磷脂化合物及其用途 |
| KR20230170745A (ko) | 2021-04-16 | 2023-12-19 | 길리애드 사이언시즈, 인코포레이티드 | 아미드를 사용한 카르바뉴클레오시드를 제조하는 방법 |
| MX2023014898A (es) | 2021-06-17 | 2024-04-29 | Atea Pharmaceuticals Inc | Terapia combinada anti-vhc ventajosa. |
| CN113735929A (zh) * | 2021-07-21 | 2021-12-03 | 海化生命(厦门)科技有限公司 | 一种抗冠状病毒的化合物及其制备方法与应用 |
| WO2023023527A1 (en) | 2021-08-18 | 2023-02-23 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
| US11541071B1 (en) | 2021-12-16 | 2023-01-03 | Ascletis BioScience Co., Ltd | Nucleoside derivatives and methods of use thereof |
| CN116554249B (zh) * | 2022-01-28 | 2025-03-18 | 北京恩泰伟医药科技有限公司 | 抗病毒化合物及其用途 |
| TW202525810A (zh) | 2022-03-02 | 2025-07-01 | 美商基利科學股份有限公司 | 用於治療病毒感染的化合物及方法 |
| JP2025509635A (ja) | 2022-03-15 | 2025-04-11 | ローム・セラピューティクス・インコーポレイテッド | 疾患を治療するための化合物及び方法 |
| CN116535385B (zh) * | 2022-08-29 | 2025-03-11 | 苏州华一新能源科技股份有限公司 | 一种制备硫酸乙烯酯的方法 |
| CN116589510B (zh) * | 2023-04-20 | 2025-08-26 | 安徽大学 | 一种氟代苄基核糖中间体的制备方法与应用 |
| US12357577B1 (en) | 2024-02-02 | 2025-07-15 | Gilead Sciences, Inc. | Pharmaceutical formulations and uses thereof |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5432272A (en) | 1990-10-09 | 1995-07-11 | Benner; Steven A. | Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases |
| BR0206614A (pt) | 2001-01-22 | 2004-02-17 | Merck & Co Inc | Composto, composição farmacêutica, método para inibir a polimerase viral de rna dependente de rna e/ou inibir a replicação viral de rna dependente de rna, método para tratar uma infecção viral de rna dependente de rna, e, uso de um composto |
| AU2002252183A1 (en) * | 2001-03-06 | 2002-09-19 | Biocryst Pharmaceuticals, Inc. | Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases |
| US20040138170A1 (en) | 2002-03-06 | 2004-07-15 | Montgomery John A. | Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases |
| OA13310A (en) | 2003-09-05 | 2007-04-13 | Anadys Pharmaceuticals Inc | TLR7 ligands for the treatment of hepatitis C. |
| JP2008508319A (ja) * | 2004-07-29 | 2008-03-21 | メタバシス・セラピューティクス・インコーポレイテッド | 新規ヌクレオシド誘導体 |
| US20090318380A1 (en) * | 2007-11-20 | 2009-12-24 | Pharmasset, Inc. | 2',4'-substituted nucleosides as antiviral agents |
| WO2009086192A1 (en) | 2007-12-21 | 2009-07-09 | Alios Biopharma, Inc. | Biodegradable phosphate protected nucleotide derivatives and their use as cancer, anti viral and anti parasitic agents |
| US8475804B2 (en) * | 2009-02-20 | 2013-07-02 | U.S. Army Medical Research And Material Command | Compositions and methods for treatment of filovirus-mediated diseases |
| EP2408306A4 (en) | 2009-03-20 | 2012-11-07 | Alios Biopharma Inc | SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGUES |
| US20100240604A1 (en) * | 2009-03-20 | 2010-09-23 | Alios Biopharma, Inc. | Protected nucleotide analogs |
| EP2619215B1 (en) | 2010-09-22 | 2018-09-05 | Alios Biopharma, Inc. | Azido nucleosides and nucleotide analogs |
| CA2810928A1 (en) * | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
| WO2012040126A1 (en) * | 2010-09-22 | 2012-03-29 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
| WO2012088155A1 (en) | 2010-12-22 | 2012-06-28 | Alios Biopharma, Inc. | Cyclic nucleotide analogs |
| SG11201403364PA (en) | 2011-12-20 | 2014-07-30 | Hoffmann La Roche | 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication |
| US8980865B2 (en) | 2011-12-22 | 2015-03-17 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
| PL2794627T3 (pl) | 2011-12-22 | 2019-04-30 | Alios Biopharma Inc | Podstawione nukleozydy, nukleotydy i ich analogi |
| NZ630800A (en) | 2012-03-21 | 2016-06-24 | Alios Biopharma Inc | Methods of preparing substituted nucleotide analogs |
| NZ631601A (en) | 2012-03-21 | 2016-06-24 | Alios Biopharma Inc | Solid forms of a thiophosphoramidate nucleotide prodrug |
| UA113980C2 (uk) * | 2012-03-21 | 2017-04-10 | Аліос Біофарма, Інк. | Заміщені нуклеозиди, нуклеотиди і їх аналоги |
| WO2013142159A1 (en) | 2012-03-21 | 2013-09-26 | Alios Biopharma, Inc. | Pharmaceutical combinations comprising a thionucleotide analog |
| US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| US9012427B2 (en) | 2012-03-22 | 2015-04-21 | Alios Biopharma, Inc. | Pharmaceutical combinations comprising a thionucleotide analog |
| WO2014099941A1 (en) | 2012-12-19 | 2014-06-26 | Idenix Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
| HK1216535A1 (zh) | 2012-12-21 | 2016-11-18 | Alios Biopharma, Inc. | 取代的核苷、核苷酸及其類似物 |
| EA201590943A1 (ru) | 2012-12-21 | 2016-01-29 | Алиос Биофарма, Инк. | Замещенные нуклеозиды, нуклеотиды и их аналоги |
| TW201526899A (zh) | 2013-02-28 | 2015-07-16 | Alios Biopharma Inc | 醫藥組成物 |
| US20140309413A1 (en) | 2013-03-11 | 2014-10-16 | Vertex Pharmaceuticals Incorporated | Methods of stereoselective synthesis of substituted nucleoside analogs |
| US9504705B2 (en) | 2013-04-05 | 2016-11-29 | Alios Biopharma, Inc. | Hepatitis C viral infection treatment using a combination of compounds |
| ES2952714T3 (es) | 2013-06-26 | 2023-11-03 | Janssen Pharmaceuticals Inc | Nucleósidos sustituidos, nucleótidos y análogos de los mismos |
| AU2014302715B2 (en) | 2013-06-26 | 2018-12-06 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| EP3043803B1 (en) * | 2013-09-11 | 2022-04-27 | Emory University | Nucleotide and nucleoside compositions and their uses |
| SG10201804835VA (en) | 2013-10-11 | 2018-07-30 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
| WO2015200205A1 (en) | 2014-06-24 | 2015-12-30 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| AU2015280245A1 (en) | 2014-06-24 | 2017-01-05 | Alios Biopharma, Inc. | Methods of preparing substituted nucleotide analogs |
| SG11201610599TA (en) | 2014-06-24 | 2017-01-27 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
| WO2016014398A1 (en) | 2014-07-22 | 2016-01-28 | Alios Biopharma, Inc. | Methods for treating paramyxoviruses |
| CA2957017A1 (en) | 2014-08-05 | 2016-02-11 | Alios Biopharma, Inc. | Combination therapy for treating a paramyxovirus |
| CN107108681B (zh) | 2014-10-28 | 2021-04-06 | 詹森生物制药有限公司 | 制备取代的核苷类似物的方法 |
| MA41213A (fr) | 2014-12-19 | 2017-10-24 | Alios Biopharma Inc | Nucléosides substitués, nucléotides et analogues de ceux-ci |
| MA41441A (fr) | 2014-12-19 | 2017-12-12 | Alios Biopharma Inc | Nucléosides substitués, nucléotides et analogues de ceux-ci |
| TW201811339A (zh) | 2016-08-12 | 2018-04-01 | 美商艾洛斯生物製藥公司 | 經取代之核苷、核苷酸及其類似物 |
| WO2018081449A1 (en) | 2016-10-27 | 2018-05-03 | Alios Biopharma, Inc. | Methods for treating respiratory syncytial virus infection |
| CR20200126A (es) | 2017-09-18 | 2020-07-11 | Janssen Biopharma Inc | Nucleósidos sustituidos, nucleótidos y análogos de estos |
-
2015
- 2015-06-22 WO PCT/US2015/036958 patent/WO2015200205A1/en not_active Ceased
- 2015-06-22 MA MA040031A patent/MA40031A/fr unknown
- 2015-06-22 NZ NZ727582A patent/NZ727582A/en not_active IP Right Cessation
- 2015-06-22 TN TN2016000566A patent/TN2016000566A1/en unknown
- 2015-06-22 MX MX2016017381A patent/MX2016017381A/es unknown
- 2015-06-22 EA EA201692537A patent/EA201692537A1/ru unknown
- 2015-06-22 CA CA2952959A patent/CA2952959C/en active Active
- 2015-06-22 EP EP15810951.2A patent/EP3160475B1/en active Active
- 2015-06-22 JP JP2016575325A patent/JP6669675B2/ja not_active Expired - Fee Related
- 2015-06-22 SG SG11201610597QA patent/SG11201610597QA/en unknown
- 2015-06-22 US US14/746,138 patent/US9603863B2/en active Active
- 2015-06-22 AP AP2016009653A patent/AP2016009653A0/en unknown
- 2015-06-22 CN CN201580045400.7A patent/CN106604734B/zh active Active
- 2015-06-22 AU AU2015280234A patent/AU2015280234B2/en active Active
- 2015-06-24 TW TW104120407A patent/TW201613613A/zh unknown
-
2016
- 2016-12-18 IL IL249627A patent/IL249627A0/en unknown
- 2016-12-21 PH PH12016502563A patent/PH12016502563A1/en unknown
-
2017
- 2017-02-08 US US15/427,964 patent/US10052342B2/en active Active
-
2018
- 2018-08-20 US US16/105,859 patent/US10780105B2/en active Active
-
2020
- 2020-08-24 US US17/001,512 patent/US11590155B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| TW201613613A (en) | 2016-04-16 |
| EP3160475A1 (en) | 2017-05-03 |
| EA201692537A1 (ru) | 2017-05-31 |
| SG11201610597QA (en) | 2017-01-27 |
| US20150366887A1 (en) | 2015-12-24 |
| US10052342B2 (en) | 2018-08-21 |
| CA2952959A1 (en) | 2015-12-30 |
| WO2015200205A1 (en) | 2015-12-30 |
| EP3160475C0 (en) | 2024-01-03 |
| US11590155B2 (en) | 2023-02-28 |
| IL249627A0 (en) | 2017-02-28 |
| CN106604734A (zh) | 2017-04-26 |
| CN106604734B (zh) | 2021-08-13 |
| US20170143751A1 (en) | 2017-05-25 |
| TN2016000566A1 (en) | 2018-04-04 |
| JP2017519780A (ja) | 2017-07-20 |
| US20190054108A1 (en) | 2019-02-21 |
| EP3160475B1 (en) | 2024-01-03 |
| MA40031A (fr) | 2015-12-30 |
| AP2016009653A0 (en) | 2016-12-31 |
| AU2015280234A1 (en) | 2017-01-12 |
| US20210106604A1 (en) | 2021-04-15 |
| EP3160475A4 (en) | 2018-02-21 |
| US10780105B2 (en) | 2020-09-22 |
| JP6669675B2 (ja) | 2020-03-18 |
| NZ727582A (en) | 2018-06-29 |
| CA2952959C (en) | 2023-03-07 |
| US9603863B2 (en) | 2017-03-28 |
| PH12016502563A1 (en) | 2017-04-17 |
| AU2015280234B2 (en) | 2021-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016502563A1 (en) | Substituted nucleosides, nucleotides and analogs thereof | |
| PH12016502564A1 (en) | Substituted nucleosides, nucleosides and analogs thereof | |
| MX2017008183A (es) | Nucleosidos sustituidos, nucleotidos y analogos de estos. | |
| MX2017008184A (es) | Nucleosidos sustituidos, nucleotidos y analogos de estos. | |
| PH12016500660A1 (en) | Substituted nucleosides, nucleotides and analogs thereof | |
| PH12015501423A1 (en) | Substituted nucleosides, nucleotides and analogs thereof | |
| PH12020551055A1 (en) | Methods for treating filoviridae virus infections | |
| WO2018031818A3 (en) | Substituted nucleosides, nucleotides and analogs thereof | |
| PH12015502799A1 (en) | Substituted nucleosides, nucleotides and analogs thereof | |
| PH12016502555A1 (en) | Methods of preparing substituted nucleotide analogs | |
| HK1243714A1 (zh) | 制备取代的核苷类似物的方法 | |
| HK1216535A1 (zh) | 取代的核苷、核苷酸及其類似物 | |
| HK1224229A1 (zh) | 取代的核苷，核苷酸及其类似物 | |
| LT3265102T (lt) | Beta-d-2'-deoksi-2'alfa-fluor-2'-beta-c-pakeistieji-2-modifikuoti-n6- pakeistieji purino nukleotidai, skirti hcv gydymui |